Mizuho Maintains Neutral on Biogen, Raises Price Target to $300
Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $244 to $300.
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam’s Clinical Collaboration, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Where Biogen Stands With Analysts
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
Biogen And Eisai To Present ADUHELM Data At Alzheimer’s Association International Conference 2021
Item-level analysis from EMERGE trial shows consistency in slowing decline across cognitive, functional and behavioral measures in early Alzheimer's disease
Presentations include an assessment of the
Biogen And Ionis Highlight Presentation Of Topline Data From Phase 1b Study Of BIIB080/IONIS-MAPTRx Showing Drug Met Safety And Tolerability Objective At AAIC
Biogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that
Biogen Releases Several Posters From Alzheimer’s Conference (Links In Body)
https://investors.biogen.com/static-files/3e7bed88-8a2a-4cac-926a-5b5e7f88261e
Benzinga Pro’s Top 5 Stocks To Watch For Monday, Jul. 26, 2021: BIIB, F, BBIG, PWSC, DNUT
Today's 5 Stock Ideas:
Biogen (BIIB) - Results of the company's Phase 1b study for a candidate to help treat patients with mild Alzheimer's expected out on Monday.
Ford Motor (F) -
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Biogen Highlights Presentation Of Data From ADUHELM, Alzheimer’s Disease Portfolio At Alzheimer’s Association Int’l. Conference
Biogen Inc. (NASDAQ:BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer's disease clinical development portfolio at the Alzheimer's Association International